Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies.
Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, the drug causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Its pharmaco-dynamics are reviewed in this article, along with the clinical experiences in patients with hypertensive urgencies and emergencies. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam influsion.
Post
J B
JB
Department of Medicine, Albert Einstein College of Medicine/Montefiore-Medical Center, Bronx, New York, USA.
Frishman
W H
WH
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004347:Drug Interactions; D004630:Emergencies; D018818:Fenoldopam / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects
D000959:Antihypertensive Agents; D018491:Dopamine Agonists; D018818:Fenoldopam